13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001952142
Total reported value
$580.5M
$580.5M
57 檔
16.6%
At the close of Q1 2025, Stempoint Capital LP disclosed equity holdings valued at approximately $580.5M, spread across 57 reported holdings.
During Q1 2025, Stempoint Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, SNDX, SRRK) accounted for 16.6% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 8.29% | +0.08% | -4.94% | |
| 2 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 6.26% | -5.45% | EXIT | |
| 3 | SRRK | Scholar Rock Holding CORP | Stock-Other | 5.80% | -7.59% | +112.62% | |
| 4 | ACLXGBX | Arcellx Inc | Stock-Other | 5.73% | — | — | |
| 5 | ✓ | Merus N V | Stock-Other | 4.65% | — | -43.60% | |
| 6 | IMVT | Immunovant Inc | Stock-Other | 4.65% | -1.76% | -23.70% | |
| 7 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 4.32% | — | — | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 4.30% | — | +31.10% | |
| 9 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.59% | -0.16% | +64.72% | |
| 10 | JANX | Janux Therapeutics Inc | Stock-Other | 2.94% | — | +134.49% | |
| 11 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.94% | -0.78% | -26.93% | |
| 12 | DNLI | Denali Therapeutics Inc | Stock-Other | 2.89% | -1.57% | EXIT | |
| 13 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.72% | — | -7.58% | |
| 14 | QURE | uniQure N.V. | Stock-Other | 2.47% | +0.46% | +712.27% | |
| 15 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.30% | — | — | |
| 16 | CGON | Cg Oncology Inc | Stock-Other | 2.26% | -0.71% | — | |
| 17 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.24% | — | — | |
| 18 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 2.21% | -1.42% | -73.98% | |
| 19 | INSM | Insmed Inc | Stock-Healthcare | 2.12% | — | -18.34% | |
| 20 | ALKS | Alkermes plc | Stock-Healthcare | 2.02% | +1.70% | -53.87% | |
| 21 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.02% | — | — | |
| 22 | BHVN | Biohaven Ltd. | Stock-Other | 1.92% | +0.24% | +34.41% | |
| 23 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.92% | -0.53% | +79.06% | |
| 24 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.75% | — | — | |
| 25 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 1.63% | -0.01% | +1.63% | |
| 26 | TARA | Protara Therapeutic Inc | Stock-Other | 1.62% | — | +258.18% | |
| 27 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.43% | — | -50.96% | |
| 28 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.34% | -1.75% | EXIT | |
| 29 | SRZN | Surrozen Inc | Stock-Other | 0.90% | -0.21% | -31.30% | |
| 30 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.76% | -1.12% | -65.25% | |
| 31 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.76% | +0.30% | +24.52% | |
| 32 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.74% | — | — | |
| 33 | ASND | Ascendis Pharma A/S | Stock-Other | 0.73% | — | — | |
| 34 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.72% | — | — | |
| 35 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.70% | +0.02% | — | |
| 36 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 37 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.68% | -0.66% | — | |
| 38 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.58% | — | -78.94% | |
| 39 | ABUS | Arbutus Biopharma CORP | Stock-Other | 0.52% | — | — | |
| 40 | ✓ | Stock-Other | 0.49% | — | — | ||
| 41 | GERN | Geron CORP | Stock-Other | 0.49% | — | — | |
| 42 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.35% | — | — | |
| 43 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.30% | — | — | |
| 44 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.29% | — | — | |
| 45 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.28% | -1.76% | EXIT | |
| 46 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.25% | — | — | |
| 47 | IFRX | InflaRx N.V. | Stock-Other | 0.24% | +1.25% | NEW | |
| 48 | SLDB | Solid Biosciences Inc | Stock-Other | 0.23% | +0.35% | — | |
| 49 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.23% | — | -87.54% | |
| 50 | MBX | Mbx Biosciences Inc | Stock-Other | 0.23% | -2.85% | EXIT |
According to official SEC Form 13F filings, Stempoint Capital LP reported a total U.S. public equity portfolio value of $580.5M across 57 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2025, Stempoint Capital LP's top holdings by market value included ROIV (8.3%)、SNDX (6.3%)、SRRK (5.8%). The largest single position, ROIV, represented 8.3% of total portfolio value.
In Q1 2025, Stempoint Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.